bluuebunny/crossref_metadata_2025_split huggingface dataset:
Humanoids for teaching and training coronary artery bypass surgery to the next generation of cardiac surgeons
Authors: Tozzi Piergiorgio , Ferrari Enrico , Reuthebuch Oliver , Matt Peter , Huber Christoph , Eckstein Friedrich , Kirsch Matthias , Mestres Carlos A 
Published: October 2021

Abstract

OBJECTIVES
Technical skills are an essential component of cardiac surgery, and the operating room is becoming an even more challenging environment for trainees who want to acquire such skills. Simulation, which partially overcomes this limitation, represents a valid adjunct to surgical education. We describe an original simulator and provide results in terms of trainees’ evaluations and ratings.

METHODS
We used a humanoid that is a silicone replica of the chest of an adult human that provides a complete anatomical platform for hands-on skin-to-skin practice of surgical techniques in arrested heart coronary artery bypass graft (CABG) surgery cases. Learners were residents in cardiac surgery. The teaching sessions included 2 full three-vessel CABG procedures using both mammary arteries and a hydrogel vein. Five board-certified cardiovascular surgeons scored the surgical activity of all trainees. The trainees were asked to complete an exit questionnaire to evaluate their course.

RESULTS
Overall, 16 residents participated in the simulation, including 5 women and 11 men, with a mean age of 30 ± 4 years, all of whom had at least 2 years of cardiac surgery training. All participants completed the 2 CABG operations. Three mammary arteries (4.6%) were seriously damaged during harvesting. In 1 case (3.1%), an aortic tear occurred during aortic cannulation. Each trainee performed overall 6 distal and 2 proximal coronary anastomoses. All participants agreed that the ‘humanoid reproduces real-life situations, the feeling is realistic, and they are now more confident in performing coronary anastomosis’.

CONCLUSIONS
Trainees involved in this simulation curriculum acquired and refined technical skills that could be applied directly to human patients. In addition, we were able to foster a higher level of teamwork within the operating room team.
Recommendations for Screening and Diagnosis of Chagas Disease in the United States
Authors: Forsyth Colin J , Manne-Goehler Jennifer , Bern Caryn , Whitman Jeffrey , Hochberg Natasha S , Edwards Morven , Marcus Rachel , Beatty Norman L , Castro-Sesquen Yagahira E , Coyle Christina , Stigler Granados Paula , Hamer Davidson , Maguire James H , Gilman Robert H , Meymandi Sheba 
Published: October 2021

Abstract

Background
Chagas disease affects an estimated 326 000–347 000 people in the United States and is severely underdiagnosed. Lack of awareness and clarity regarding screening and diagnosis is a key barrier. This article provides straightforward recommendations, with the goal of simplifying identification and testing of people at risk for US healthcare providers.

Methods
A multidisciplinary working group of clinicians and researchers with expertise in Chagas disease agreed on 6 main questions, and developed recommendations based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, after reviewing the relevant literature on Chagas disease in the United States.

Results
Individuals who were born or resided for prolonged time periods in endemic countries of Mexico and Central and South America should be tested for Trypanosoma cruzi infection, and family members of people who test positive should be screened. Women of childbearing age with risk factors and infants born to seropositive mothers deserve special consideration due to the risk of vertical transmission. Diagnostic testing for chronic T. cruzi infection should be conducted using 2 distinct assays.

Conclusions
Increasing provider-directed screening for T. cruzi infection is key to addressing this neglected public health challenge in the United States.
Mycotoxin deactivator improves performance, antioxidant status, and reduces oxidative stress in nursery pigs fed diets containing mycotoxins
Authors: Santos Erika Vivian , Fontes Dalton Oliveira , Benfato Mara da Silveira , Hackenhaar Fernanda Schäfer , Salomon Tiago , Jacob David Vani , Prévéraud Damien , Araujo Wagner Azis Garcia , da Glória Eduardo Maria , Domingos Rodrigo Lima , Lopes Idael Mateus Goes , Guedes Lis Lorena Melúcio , Lima Valesca Ribeiro , Cardoso Larissa Alves , Silva Bruno Alexander Nunes 
Published: October 2021

AbstractIngestion of mycotoxins can result in many problems, including decreased growth rates and immune suppression. The present study aimed to evaluate the impact of the supplementation of a mycotoxin deactivator composed by adsorbent clay minerals; inactivated fermentation extracts of Saccharomyces cerevisiae; and blend of antioxidants, organic acids, and botanicals in diets containing added mycotoxins for nursery pigs on their performance and antioxidant status. Ninety pigs weaned with 24 d of age (7.12 ± 0.68 kg of BW) were used. Pigs were housed in pens of three animals each according to body weight, litter origin, and sex. The dietary treatments consisted of feeding the pigs with a standard control diet as negative control (NC; mycotoxin levels at accepted regulatory Brazilian Ministry of Agriculture standards; deoxynivalenol (DON): &lt;100 μg/kg; zearalenone (ZEA): &lt;20 μg/kg; fumonisins (FB): &lt;1 mg/kg); the standard diet added with mycotoxins to reach a low contamination level is considered as positive low (PCL−; DON: 900 μg/kg; ZEA: 100 μg/kg; FB: 5,000 μg/kg) without deactivator; a positive low added the deactivator at an inclusion rate of 1 kg/ton (PCL+); the standard diet added with mycotoxins to reach a high contamination level is considered as positive high (PCH−; DON: 4,500 μg/kg; ZEA: 500 μg/kg; FB: 18,000 μg/kg) without the deactivator; and a positive high added the deactivator at an inclusion rate of 5 kg/ton (PCH+). Pigs were individually weighed at the beginning and at the end of each phase and feed intake recorded based on daily pen intake during the experiment. On days 7, 19, 34, and 43 post-weaning, blood samples were drawn for antioxidant analyses. Antioxidant enzymes (glutathione peroxidase [GPx] and total superoxide dismutase [TSOD]), vitamins [Vit A, E, and C], and malondialdehyde [MDA]) were evaluated in erythrocyte and plasma samples. Pigs challenged with mycotoxins presented lower performance traits, decrease in the efficiency of central antioxidant systems (↓GPx, ↓TSOD, ↓Vit A, ↓Vit E, and ↓Vit C), and a higher oxidative damage to lipids (↑MDA) when compared with the control and deactivator-associated treatments. Our findings showed that the use of a mycotoxin deactivator can mitigate the negative impacts on performance and oxidative stress when animals are subjected to diets contaminated by different levels of mycotoxins.
Herbage mass and allowance and animal genotype affect daily herbage intake, productivity, and efficiency of beef cows grazing native subtropical grassland
Authors: Do Carmo Martin , Genro Teresa C M , Cibils Andrés F , Soca Pablo M 
Published: October 2021

Abstract
The beef sector in Campos grasslands must increase animal productivity without external inputs, while reducing environmental impact. The objective of this study was to estimate herbage intake (g/metabolic body weight [MBW]/d) of straightbred (Hereford/Angus) and crossbred (F1 of Hereford × Angus) beef cows grazing subtropical native grassland with High and Low herbage allowance (HA, 5 vs. 3 kg DM/kg bodyweight [BW]) during gestation and lactation and its relationship with biological efficiency of cow-calf productivity. Herbage intake (estimated via n-alkanes C32:C33 ratio) was measured during early (Ge1, −163 d prior calving) and mid to late [Gm1 (−83) and Gm2 (−90 d prior calving)] gestation and lactation (L0, L1, and L2, 60, 47, and 31d following calving) periods in 24 to 36 cows, selected to create 8 groups (4 per block) of HA × cow genotype treatment. Cows grazed native grassland year-round, under High and Low HA (except in winter). We analyzed the effect of cow genotype (straightbred vs. crossbred cows) and HA (High vs. Low) on herbage mass and height, daily herbage intake rate (DMI), cow body condition score (BCS), calf average daily gain (ADG) and BW at weaning (BWW) and g of calf weaned/kg DMI. High allowance improved DMI during lactation periods (High 115.6 vs. Low 94.1 ± 5.3; P &lt; 0.05 g/MBW/d). Crossbred cows decreased DMI during gestation (Crossbred 81 vs. Straightbred 94 ± 4.3; P = 0.05 g/MBW/d) compared with straightbred cows. Crossbred and High HA improved biological efficiency, 40.0 vs. 26.2 and 36.0 vs. 29.7 g of calf/kg DMI, respectively. High allowance increased herbage mass and sites with greater canopy height that allow greater DMI, positively associated with cow BCS at weaning, calf ADG, BWW, and g of calf/kg DMI. Crossbred cows reduced DMI during gestation showing no greater annual DMI. Animal productivity and biological efficiency can be improved using High HA and crossbred cows, which should decrease the environmental impact of cow-calf systems.
Black Insecurity at the End of the World
Authors: Mann Justin L 
Published: October 2021

Abstract“Black Insecurity at the End of the World” examines the sensibility I term black insecurity by reading Colson Whitehead’s 2010 novel Zone One against a backdrop of bioinsecurity and police murder of black people. The 2014 Ebola outbreak in West Africa and uprisings in Ferguson, Missouri, from the same year, when situated in dialogue with Whitehead’s text, show that black insecurity reframes the spatio-temporal notion of survival by unmasking security structures as dead and dying. Engaged from the standpoint of ongoing racial justice protests and stay-at-home conditions of the COVID-19 pandemic, “Black Insecurity at the End of the World” argues that black speculative fictions uniquely expose the false premises of securitization and show that black love is an essential process for unmaking the forces of anti-Blackness.
Trophic ecology of the Hubb's octopus Octopus hubbsorum (Cephalopoda: Octopodidae) in the central Mexican Pacific
Authors: Serrano-Tadeo Martín , Flores-Ortega Juan Ramón , Godínez-Domínguez Enrique , Granados-Amores Jasmín , Zavala-Leal Oscar Iram , Granados-Amores Andrés 
Published: October 2021

ABSTRACT
The diet of the Hubb's octopus Octopus hubbsorum along the coast of Acapulco, Guerrero, Mexico, was determined by analysing the stomach contents of 413 individuals collected monthly between February 2017 and March 2018. Most stomachs (74.3%) presented contents, while 25.7% were empty. Sixty prey items were identified and grouped into 16 categories. The most frequent prey items were Petrolisthes sanfelipensis, Clastotoechus diffractus, Petrolisthes hians and Alpheus spp. Smith's index indicated that O. hubbsorum follows a generalist diet for each hydroclimatic season, sex and size class (1: juvenile; 2: young adult; 3: mature adult). Cannibalism was frequent among males, less so among females. Pianka's index revealed a higher overlap among the three size classes of both sexes during the dry season, while during the rainy season the overlap was reduced for size classes 2 and 3 in both sexes. The average isotopic values overall were δ13C −14.96‰ (±0.08) and δ15N 13.02‰ (±0.09). A significant difference (P = 0.005) was observed in δ13C among hydroclimatic seasons (rainy and dry) and size classes, while for δ15N a significant difference (P = 0.013) was observed between seasons. Stomach content analysis gave values of the trophic position of O. hubbsorum ranging from 3.57 to 3.72, whereas the values obtained using stable isotope analysis, using δ15N, ranged from 3.52 to 3.86. Variation was observed in isotopic niche size and Layman's metrics among hydroclimatic seasons. A higher isotopic niche overlap was observed between size classes 2 and 3 during the dry season. The rocky shore ecosystem has been heavily exploited by artisanal fisheries (fish and invertebrates). A more integrated, ecosystem-based management of these fisheries requires an understanding of their trophic structure.
Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data
Authors: Bota Daniela A , Mason Warren , Kesari Santosh , Magge Rajiv , Winograd Benjamin , Elias Ileana , Reich Steven D , Levin Nancy , Trikha Mohit , Desjardins Annick 
Published: October 2021

Abstract

Background
This phase I/II trial in patients with recurrent glioblastoma (GBM) evaluates the safety and preliminary efficacy of marizomib, an irreversible pan-proteasome inhibitor that crosses the blood–brain barrier.

Methods
Part A assessed the safety and efficacy of marizomib monotherapy. In Part B, escalating doses of marizomib (0.5–0.8 mg/m2) in combination with bevacizumab were evaluated. Part C explored intra-patient dose escalation of marizomib (0.8–1.0 mg/m2) for the combination.

Results
In Part A, 30 patients received marizomib monotherapy. The most common AEs were fatigue (66.7%), headache (46.7%), hallucination (43.3%), and insomnia (43.3%). One patient (3.3%) achieved a partial response. In Part B, the recommended phase II dose of marizomib was 0.8 mg/m2 when combined with bevacizumab 10 mg/kg. In Part C, dose escalation to 1.0 mg/m2 was not tolerated. Pooled analysis of 67 patients treated with marizomib ≤0.8 mg/m2 and bevacizumab showed a nonoverlapping safety profile consistent with the known safety profile of each agent: the most common grade ≥3 AEs were hypertension (16.4%), confusion (13.4%), headache (10.4%), and fatigue (10.4%). The overall response rate was 34.3%, including 2 patients with complete response. Six-month progression-free survival was 29.8%; median overall survival was 9.1 months.

Conclusions
The safety profile of marizomib as monotherapy and in combination with bevacizumab was consistent with previous observations that marizomib crosses the blood–brain barrier. Preliminary efficacy did not demonstrate a meaningful benefit of the addition of marizomib to bevacizumab for the treatment of recurrent GBM.
Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing
Authors: Stevanovski Igor , Chintalaphani Sanjog R. , Gamaarachchi Hasindu , Ferguson James M. , Pineda Sandy S. , Scriba Carolin K. , Tchan Michel , Fung Victor , Ng Karl , Cortese Andrea , Houlden Henry , Dobson-Stone Carol , Fitzpatrick Lauren , Halliday Glenda , Ravenscroft Gianina , Davis Mark R. , Laing Nigel G. , Fellner Avi , Kennerson Marina , Kumar Kishore R. , Deveson Ira W. 
Published: October 2021

ABSTRACTShort-tandem repeat (STR) expansions are an important class of pathogenic genetic variants. Over forty neurological and neuromuscular diseases are caused by STR expansions, with 37 different genes implicated to date. Here we describe the use of programmable targeted long-read sequencing with Oxford Nanopore’s ReadUntil function for parallel genotyping of all known neuropathogenic STRs in a single, simple assay. Our approach enables accurate, haplotype-resolved assembly and DNA methylation profiling of expanded and non-expanded STR sites. In doing so, the assay correctly diagnoses all individuals in a cohort of patients (n = 27) with various neurogenetic diseases, including Huntington’s disease, fragile X syndrome and cerebellar ataxia (CANVAS) and others. Targeted long-read sequencing solves large and complex STR expansions that confound established molecular tests and short-read sequencing, and identifies non-canonical STR motif conformations and internal sequence interruptions. Even in our relatively small cohort, we observe a wide diversity of STR alleles of known and unknown pathogenicity, suggesting that long-read sequencing will redefine the genetic landscape of STR expansion disorders. Finally, we show how the flexible inclusion of pharmacogenomics (PGx) genes as secondary ReadUntil targets can identify clinically actionable PGx genotypes to further inform patient care, at no extra cost. Our study addresses the need for improved techniques for genetic diagnosis of STR expansion disorders and illustrates the broad utility of programmable long-read sequencing for clinical genomics.One sentence summaryThis study describes the development and validation of a programmable targeted nanopore sequencing assay for parallel genetic diagnosis of all known pathogenic short-tandem repeats (STRs) in a single, simple test.
Efficacy of COVID-19 vaccines in immunocompromised patients: A systematic review and meta-analysis
Authors: Lee Ainsley Ryan Yan Bin , Wong Shi Yin , Chai Louis Yi Ann , Lee Soo Chin , Lee Matilda , Muthiah Mark Dhinesh , Tay Sen Hee , Teo Chong Boon , Tan Benjamin Kye Jyn , Chan Yiong Huak , Sundar Raghav , Soon Yu Yang 
Published: October 2021

AbstractObjectiveTo compare the efficacy of COVID 19 vaccines between those with immunocompromised medical conditions and those who are immunocompetentDesignSystematic review and meta-analysisData sourcesPubMed, EMBASE, CENTRAL, CORD-19 and WHO COVID-19 research databases were searched for eligible comparative studies published between 1 December 2020 and 3 September 2021. ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform were searched in September 2021 to identify registered yet unpublished or ongoing studies.Study selectionProspective observational studies which compared the efficacy of COVID-19 vaccination between those with immunocompromising medical conditions and those who were immunocompetent were included. Two reviewers independently screened for potentially eligible studies.Data extractionThe primary outcomes of interest were cumulative incidence of seroconversion after first and second doses of COVID vaccination. Secondary outcomes included SARS-CoV-2 antibody titre level after first and second doses of COVID-19 vaccination. After duplicate data abstraction, a frequentist random effects meta-analysis was conducted. Risk of bias was assessed using the ROBINS-I tool. Certainty of evidence was assessed using the GRADE approach.ResultsAfter screening 3283 studies, 42 studies that met our inclusion criteria were identified. 18 immunocompromised cohorts from 17 studies reported seroconversion in immunocompromised patients compared to healthy controls after the first dose and 30 immunocompromised cohorts in 28 studies reporting data after the second dose.Among immunocompromised groups, in incremental order, transplant recipients had the lowest pooled risk ratio of 0.06 (95%CI: 0.04 to 0.09, I^2=0%, p=0.81) (GRADE=Moderate) followed by haematological cancer patients at 0.36 (95%CI: 0.21 to 0.62, I^2 = 89%, p<0.01) (GRADE=Moderate), solid cancer patients at 0.40 (95%CI: 0.31 to 0.52, I^2 = 63%, p=0.03) (GRADE=Moderate) and IMID patients at 0.66 (95%CI: 0.48 to 0.91, I^2=81%, p<0.01) (GRADE=Moderate).After the second dose, the lowest pooled risk ratio was again seen in transplant recipients at 0.29 (95%CI: 0.21 to 0.40, I^2=91%, p<0.01) (GRADE=Moderate), haematological cancer patients at 0.68 (95%CI: 0.57 to 0.80, I^2=68%, p=0.02) (GRADE=Low), IMID patients at 0.79 (95%CI: 0.72 to 0.86, I^2=87%, p<0.01) (GRADE=Low) and solid cancer at 0.92 (95%CI: 0.89 to 0.95, I^2=26%, p=0.25) (GRADE=Low).ConclusionSeroconversion rates and serological titres are significantly lower in immunocompromised patients with transplant recipients having the poorest outcomes. Additional strategies on top of the conventional 2-dose regimen will likely be warranted, such as a booster dose of the vaccine.Systematic review registrationPROSPERO CRD42021272088
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom
Authors: Perez-Lloret Santiago , Petrovsky Nikolai , Alami Abdallah , Crispo James A.G. , Mattison Donald , Otero-Losada Matilde , Capani Francisco , Krewski Daniel 
Published: October 2021

ABSTRACTObjectiveThe information on neurologic or psychiatric adverse reactions to the COVID-19 vaccines is limited. Our objective was to examine the odds of neurological and psychiatric adverse reactions to BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccines.MethodsWe analyzed all Adverse Vaccine Reaction reports to the United Kingdom Medicines and Healthcare products Regulatory Agency between December 9, 2020 and June 30, 2021 that mentioned the BNT162b2 or ChAdOx1 vaccines. We compared the rates of adverse neurological and psychiatric reactions with ChAdOx1 to those with BNT162b2. P-values were obtained by a Bonferroni-adjusted Z-test for proportions.ResultsAs of June 30, 2021, 53.2 M doses of ChAdOx1 and 46.1 M doses of BNT162b2 had been administered. We extracted information from 300,518 distinct reports. The number of individual adverse neurologic or psychiatric reaction reports were less than 200/M doses administered, except headache which was reported in 1,550 and 395 cases/M doses of ChAdOx1 and BNT162b2, respectively. Compared to BNT162b2, cerebral hemorrhagic or thrombotic events, headaches and migraines, Guillain-Barre syndrome and paresthesias, tremor and freezing, delirium, hallucinations, nervousness, poor sleep quality, and postural dizziness were more frequently reported with ChAdOx1. Reactions more frequently reported with BNT162b2 than ChAdOx1 were Bell’s palsy, facial paralysis, dysgeusia, anxiety, and presyncope or syncope.ConclusionSignificant differences in the neurologic and psychiatric adverse event profiles of the ChAdOx1 and BNT162b2 vaccines may exist, emphasizing the need for additional research. The beneficial and protective effects of the COVID-19 vaccines far outweigh the low potential risk of neurologic and psychiatric reactions.
Genomic profile in TGCT Mexican patients reveals a potential biomarker of sensitivity to platinum-based therapy
Authors: González-Barrios Rodrigo , Alcaraz Nicolás , Montalvo-Casimiro Michel , Cervera Alejandra , Munguia-Garza Paulina , Arriaga-Canon Cristian , Hinojosa-Ugarte Diego , Sobrevilla-Moreno Nora , Torres-Arciga Karla , Mendoza-Perez Julia , Diaz-Chavez José , Cortes Carlo Cesar , Scavuzzo Ana , Castro-Hernández Clementina , Martínez-Cedillo Jorge , Pérez-Montiel Delia , Jiménez-Ríos Miguel , Herrera Luis A. 
Published: October 2021

AbstractDespite having a favorable response to platinum-based chemotherapies, ∼15% of Testicular Germ Cell Tumor (TGCT) patients are platinum resistant. Mortality rates among Latin American countries have remained constant over time, which makes the study of this population of particular interest. To gain insight into this phenomenon, we conducted whole-exome sequencing, microarray-based comparative genomic hybridization, and copy number analysis of 32 tumors from a Mexican cohort, of which 18 were platinum sensitive and 14 were platinum resistant. We incorporated analyses of mutational burden, driver mutations, SNV and CNV signatures. We observed that sensitivity to chemotherapy does not seem to be explained by any of the mutations detected. Instead, we uncovered CNVs, particularly amplification of 2q11.1 as a novel variant with chemosensitivity biomarker potential. DNA breakpoints in genes were also investigated and might represent an interesting research opportunity. Our data sheds light into understanding platinum resistance in a poorly characterized population.